



ACCREDITATION DOCUMENT

F-06/02
Issue Date: 18/08/2020
Rev. No: 09
LAB 222

Accreditation No: LAB 222

Awarded to

**Quality Control Laboratory
CCL Pharmaceuticals (Pvt.) Limited
Plot # 710, Sundar Industrial Estate,
Lahore, Pakistan**

The scope of accreditation is in accordance with the standard specifications outlined in the following page(s) of this document. The accredited scope shall be visible and legible in areas such as customer service, sample-receiving section etc and shall not mislead its users.

The accreditation was first time granted on **23-04-2021** by Pakistan National Accreditation Council.

The laboratory complies with the requirements of **ISO/IEC 17025:2017**.

The accreditation requires regular surveillance, and is valid until **22-04-2027**.

The decision of accreditation made by Pakistan National Accreditation Council implies that the organization has been found to fulfill the requirements for accreditation within the scope.

The organization however, itself is responsible for the results of performed measurements/tests.

PAKISTAN NATIONAL ACCREDITATION COUNCIL

13-06-2024

Date

-SD-

Director General



ACCREDITATION DOCUMENT

F-06/02
Issue Date: 18/08/2020
Rev. No: 09
LAB 222

Testing Laboratory.

Accreditation Scope of Quality Control Laboratory
CCL Pharmaceuticals (Pvt.) Limited
Plot # 710, Sundar Industrial Estate,
Lahore, Pakistan.

Permanent laboratory premises

Materials/Products tested	Testing field (e.g. environmental testing or mechanical testing)	Types of test/ Properties measured	Reference to standardized method (e.g. ISO 14577-1:2003)/ Internal method reference
Isopropyl Myristate	Pharmaceutical Testing	Refractive Index	British Pharmacopoeia 2024; Volume I; Isopropyl Myristate
Lecetam Tablet 500mg	Pharmaceutical Testing	Assay of Levetiracetam	USP NF, 2024 Volume 3, Levetiracetam Tablets
Lecetam Tablet 250mg	Pharmaceutical Testing	Assay of Levetiracetam	USP NF, 2024 Volume 3, Levetiracetam Tablets
Sitapin Tablet 100mg	Pharmaceutical Testing	Assay of Sitagliptin	USP NF 2024, Volume 4, Sitagliptin Tablets
Sitapin Tablet 50mg	Pharmaceutical Testing	Assay of Sitagliptin	USP NF 2024, Volume 4, Sitagliptin Tablets
Purified Water	Pharmaceutical Testing	pH	USP NF 2024; pH
	Pharmaceutical Testing	Conductivity	USP NF 2024; Water Conductivity
	Microbiological Testing (Pharmaceutical)	Total Coliform (Qualitative)	APHA-9222 B/Standard Total Coliform Membrane Filter Procedure/APHA 23rd Edition
	Microbiological Testing (Pharmaceutical)	Fecal Coliform [E. coli] (Qualitative)	APHA-9222 D /Thermotolerant (Fecal) Coliform Membrane Filter Procedure/ APHA 23rd Edition
	Microbiological Testing (Pharmaceutical)	Total Aerobic Microbial Count	British Pharmacopoeia 2024; Volume II; Purified Water
Source Water	Microbiological Testing (Pharmaceutical)	Total Coliform (Qualitative)	APHA-9222 B/Standard Total Coliform Membrane Filter Procedure/APHA 23rd Edition
	Microbiological Testing (Pharmaceutical)	Fecal Coliform [E. coli] (Qualitative)	APHA-9222 D /Thermotolerant (Fecal) Coliform Membrane Filter Procedure/ APHA 23rd Edition
	Microbiological Testing (Pharmaceutical)	Total Aerobic Microbial Count	British Pharmacopoeia 2024; Volume II; Purified Water

13-06-2024
Date

-Sd-
Director